T1	Participants 44 63	hepatitis B patient
T2	Participants 227 255	chronic hepatitis B patients
T3	Participants 329 369	Seventy-two chronic hepatitis B patients
T4	Participants 516 617	The patients in different groups were treated with different doses of recombinant hepatitis B vaccine
T5	Participants 1151 1185	patients who were ELISPOT positive
T6	Participants 1738 1772	patients who were ELISPOT positive
